NPPA caps retail prices for 23 new drug formulations in India
India’s drug-pricing regulator has notified maximum retail prices, excluding GST, for 23 new formulations spanning diabetes, cardiac, mental-health, infection and pain therapies. Identical products launched within 12 months must be priced at or below the notified level.
India's NPPA fixed maximum retail prices, excluding GST, for 23 new drug formulations across diabetes, cardiac, mental-health, infection and pain therapies. Manufacturers must not exceed notified prices, while identical launches within 12 months must match or stay below them.
Why this matters
The NPPA pricing action follows a recent House panel call for tighter price and margin controls on non-scheduled medicines, extending scrutiny of medicine affordability and retail pricing.
The retail-company theme is accelerating, up +230000% QoQ.